Astrana Health (NASDAQ:ASTH) Price Target Lowered to $45.00 at BTIG Research

Astrana Health (NASDAQ:ASTH) had its price objective cut by equities research analysts at BTIG Research from $50.00 to $45.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential upside of 76.19% from the company’s previous close.

Several other equities research analysts also recently issued reports on the company. Zacks Research raised Astrana Health from a “strong sell” rating to a “hold” rating in a research report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Astrana Health in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

Astrana Health Stock Down 23.4%

NASDAQ:ASTH traded down $7.82 during mid-day trading on Friday, reaching $25.54. The stock had a trading volume of 1,199,426 shares, compared to its average volume of 346,841. The stock has a market cap of $1.43 billion, a P/E ratio of 50.08, a PEG ratio of 0.90 and a beta of 0.80. The business’s 50 day moving average is $30.57 and its 200 day moving average is $27.96. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.59 and a quick ratio of 1.59. Astrana Health has a fifty-two week low of $21.20 and a fifty-two week high of $57.42.

Astrana Health (NASDAQ:ASTH) last posted its earnings results on Wednesday, January 10th. The company reported $0.50 EPS for the quarter. The company had revenue of $317.00 million during the quarter. Astrana Health had a net margin of 1.04% and a return on equity of 3.43%. As a group, sell-side analysts predict that Astrana Health will post 1.15 earnings per share for the current year.

Hedge Funds Weigh In On Astrana Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Astrana Health by 4.5% during the first quarter. Vanguard Group Inc. now owns 4,898,992 shares of the company’s stock worth $151,918,000 after purchasing an additional 213,033 shares during the period. SteelPeak Wealth LLC lifted its position in shares of Astrana Health by 7.8% during the 3rd quarter. SteelPeak Wealth LLC now owns 579,937 shares of the company’s stock worth $16,441,000 after buying an additional 41,761 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Astrana Health by 6.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 499,529 shares of the company’s stock worth $15,490,000 after buying an additional 28,200 shares during the period. Diamond Hill Capital Management Inc. boosted its stake in Astrana Health by 33.0% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 361,264 shares of the company’s stock valued at $10,242,000 after buying an additional 89,733 shares in the last quarter. Finally, Invesco Ltd. grew its position in Astrana Health by 13.0% in the first quarter. Invesco Ltd. now owns 292,043 shares of the company’s stock valued at $9,056,000 after acquiring an additional 33,523 shares during the period. 52.77% of the stock is owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.